Premium
Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma. A clinical and pharmacology report
Author(s) -
Bern Murray M.,
McDermott William,
Cady Blake,
Oberfield Richard A.,
Trey Charles,
Clouse Melvin E.,
Tullis James L.,
Parker Leroy M.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197808)42:2<399::aid-cncr2820420204>3.0.co;2-5
Subject(s) - medicine , toxicity , hepatocellular carcinoma , ascites , pharmacokinetics , gastroenterology , infusion therapy , chemotherapy , intravenous infusions , bilirubin , doxorubicin , therapeutic index , drug , pharmacology
Four patients received intraarterial (ia) hepatic infusion and 10 received intravenous (iv) adriamycin for hepatocellular carcinoma. Four of each group are evaluable. The remaining 6 patients died within 14 days of intravenous therapy and are, therefore, considered nonevaluable. Patients received 2 to 9 courses of adriamycin every 3 weeks. One half of each group of evaluable patients had partial responses (pr). The ia group had pr for 22.5 weeks (range 8 to 37). The iv group had pr 27.2 weeks (range: 16 to 38.5). Mean survival was 21 weeks for nonresponders, and 43 weeks for responders. Intraarterial infusion did not protect patients from adriamycin toxicity. Cardiac and liver toxicity were not seen, but marrow and gastrointestinal toxicity developed at 1.2 × 10 −7 M adriamycin serum level. Adriamycin disappearance curves after ia and iv therapy were similar for similar bilirubin levels, and prolonged with hyperbilirubinemia. Ascites fluid did not accumulate detectable adriamycin. Pharmacokinetics are described in this report.